Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.

All peptides
HormoneResearch Phase

Ghrelin (Native)

Intravenous
Written by Peptide Association Editorial TeamMedically reviewed by Ian Justl Ellis, MD, CPTLast reviewed Editorial policy

Overview

Ghrelin is a naturally occurring 28-amino acid peptide hormone produced primarily in the stomach with an essential octanoyl modification at serine-3 required for biological activity. It functions as the endogenous ligand for the growth hormone secretagogue receptor (GHS-R1a), stimulating growth hormone release, appetite, and gastric motility.

Mechanism of Action

Ghrelin plays a central role in energy homeostasis, feeding behavior, and metabolic regulation.

Research Summary & Key Findings

Native ghrelin has been studied in clinical research settings for cachexia, gastroparesis, and anorexia, with small trials demonstrating increased food intake and gastric emptying. Rapid enzymatic degradation and short half-life limit therapeutic utility, leading to development of synthetic analogues with improved stability. No formulation of native ghrelin has achieved regulatory approval for clinical use.

Clinical Status

Research Phase

Ghrelin (Native) is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Intravenous

References

Primary literature

Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.

Related Peptides in Hormone

No lawful pathway today

Ghrelin (Native) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.

Tell me if the status changes

One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.